D. Bernard

发表

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Dajun Yang, Su Qiu, Guoping Wang, 2008, Proceedings of the National Academy of Sciences.

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2017, Nature Communications.

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Shanghai Yu, Liu Liu, Wei Sun, 2014, Cancer research.

Computer-Aided Drug Design: Structure-Activity Relationships of Delta Opioid Ligands

Alexander D. MacKerell, D. Bernard, A. Coop, 2005 .

High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.

Liu Liu, Fang Cao, Yali Dou, 2013, Journal of the American Chemical Society.

Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.

Liu Liu, Shaomeng Wang, D. Bernard, 2015, Methods in molecular biology.

Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.

Liu Liu, Shaomeng Wang, James Delproposto, 2019, Journal of medicinal chemistry.

Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.

Liu Liu, Shaomeng Wang, J. Stuckey, 2018, Angewandte Chemie.

Small molecules block the interaction between porcine reproductive and respiratory syndrome virus and CD163 receptor and the infection of pig cells

D. Bernard, A. Garmendia, M. K. Hadden, 2020, Virology Journal.

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors.

J. Deschamps, Liu Liu, Shaomeng Wang, 2013, Journal of the American Chemical Society.

Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.

Alexander D. MacKerell, D. Bernard, A. Coop, 2007, Journal of medicinal chemistry.

Position of coordination of the lithium ion determines the regioselectivity of demethylations of 3,4-dimethoxymorphinans with L-selectride.

Alexander D. MacKerell, J. Deschamps, D. Bernard, 2005, Organic letters.

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Liu Liu, Shaomeng Wang, Dajun Yang, 2017, Journal of medicinal chemistry.

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

D. Bernard, Yujun Zhao, Shaomeng Wang, 2014, Journal of medicinal chemistry.

A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

Liu Liu, Shaomeng Wang, D. McEachern, 2013, Journal of medicinal chemistry.

Structure-based design of conformationally constrained cyclic peptidomimetics to target the MLL1-WDR5 protein–protein interaction as inhibitors of the MLL1 methyltransferase activity

F. Cao, Elizabeth C. Townsend, Hacer Karatas, 2015 .

Tetrapyrrolic Pigments from Heme‐ and Chlorophyll Breakdown are Actin‐Targeting Compounds

S. Zahler, A. Vollmar, Simone Moser, 2021, Angewandte Chemie.

Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase.

Shirley Y. Lee, Liu Liu, Shaomeng Wang, 2020, ACS medicinal chemistry letters.

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.

Chao-Yie Yang, Shaomeng Wang, D. Bernard, 2017, Cold Spring Harbor perspectives in medicine.

Activating STAT6 mutations in follicular lymphoma.

M. Kaminski, Siân Jones, P. Ouillette, 2015, Blood.

Follicular lymphoma–associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR

M. Kaminski, S. Malek, Shaomeng Wang, 2019, The Journal of clinical investigation.

Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics

Shaomeng Wang, D. Bernard, Yujun Zhao, 2013 .

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Shaomeng Wang, D. Bernard, Yujun Zhao, 2012 .

Case Study: Inhibitors of the MDM2‐p53 Protein–Protein Interaction

Shaomeng Wang, S. Shangary, D. Bernard, 2010 .

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Shaomeng Wang, Yipin Lu, T. Carey, 2008, Molecular Cancer Therapeutics.

Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

Z. Nikolovska-Coleska, Jianyong Chen, D. Bernard, 2010, ACS medicinal chemistry letters.

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

Liu Liu, Shaomeng Wang, Yi Sun, 2021, Nature Communications.

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

Liu Liu, Shaomeng Wang, Yi Sun, 2017, Nature Communications.

Conformationally Sampled Pharmacophore for Peptidic δ Opioid Ligands

Alexander D. MacKerell, D. Bernard, A. Coop, 2005 .

Conformationally sampled pharmacophore for peptidic delta opioid ligands.

Alexander D. MacKerell, D. Bernard, A. Coop, 2005, Journal of medicinal chemistry.

2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate delta opioid agonists from antagonists.

Alexander D. MacKerell, Alexander D MacKerell, Andrew Coop, 2003, Journal of the American Chemical Society.

Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation

M. Kaminski, S. Malek, Shaomeng Wang, 2021, Clinical Cancer Research.

Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma

M. Kaminski, S. Malek, Shaomeng Wang, 2016, Clinical Cancer Research.

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.

F. Cao, Elizabeth C. Townsend, Hacer Karatas, 2017, Journal of medicinal chemistry.

Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.

Elizabeth C. Townsend, Hacer Karatas, Y. Dou, 2010, Journal of medicinal chemistry.

Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles

J. Deschamps, Liu Liu, Shaomeng Wang, 2014, Journal of medicinal chemistry.

Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction.

Liu Liu, Hacer Karatas, Liu Liu, 2013, Journal of medicinal chemistry.

Split Renilla Luciferase Protein Fragment-assisted Complementation (SRL-PFAC) to Characterize Hsp90-Cdc37 Complex and Identify Critical Residues in Protein/Protein Interactions*

Tao Zhang, Shaomeng Wang, Xueqi Fu, 2010, The Journal of Biological Chemistry.

Discovery of a novel SHIP1 agonist that promotes degradation of lipid-laden phagocytic cargo by microglia

J. Ha, S. Loh, D. Bernard, 2022, iScience.

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.

Liu Liu, Shaomeng Wang, Yi Sun, 2018, Journal of Medicinal Chemistry.

Targeting the MDM 2 – p 53 Protein – Protein Interaction for New Cancer Therapy : Progress and Challenges

Shaomeng Wang, D. Bernard, Yujun Zhao, 2017 .

Identification of New Compounds against PRRSV Infection by Directly Targeting CD163

D. Bernard, Yue Su, A. Garmendia, 2023, Journal of virology.

Rearrangement of 5-trimethylsilylthebaine on treatment with L-selectride: an efficient synthesis of (+)-bractazonine.

Alexander D. MacKerell, J. Deschamps, J. Flippen-Anderson, 2003, The Journal of organic chemistry.

Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

Z. Nikolovska-Coleska, Jianyong Chen, D. Bernard, 2010, ACS medicinal chemistry letters.

Split Renilla Luciferase Protein Fragment-assisted Complementation (SRL-PFAC) to Characterize Hsp90-Cdc37 Complex and Identify Critical Residues in Protein/Protein Interactions*

Tao Zhang, Shaomeng Wang, Xueqi Fu, 2010, The Journal of Biological Chemistry.